Journal article

Early-phenotype CAR-T cells for the treatment of pediatric cancers

D Meyran, RL Terry, JJ Zhu, M Haber, DS Ziegler, PG Ekert, JA Trapani, PK Darcy, PJ Neeson



Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of childhood cancers, particularly high-risk tumors that fail to respond to standard therapies. CAR-T cells have been highly successful in treating some types of hematological malignancies. However, CAR-T cells targeting solid cancers have had limited success so far for multiple reasons, including their poor long-term persistence and proliferation. Evidence is emerging to show that maintaining CAR-T cells in an early, less-differentiated state in vitro results in superior persistence, proliferation, and antitumor effects in vivo. Children are ideal candidates for receiving less-differentiated CAR-T cells..

View full abstract


Awarded by National Health and Medical Research Council program grant (NHMRC)

Funding Acknowledgements

This work was supported by the Medical Research Future Fund Australian Brain Cancer Mission, the National Health and Medical Research Council program grant (NHMRC) [grant number 1132373] . DM was supported by funding from Fondation Nuovo Soldati, Fondation de France, Tour de Cure. JJZ was supported by a generous donation from John Stephens and Roger Gyles and the Movember PCRA grant (no grant number) . RLT was supported by funding from Tour de Cure Pioneering Research Grant, the Austra-lian and New Zealand Sarcoma Association, and Xavier Kri-kori Sarcoma Research Grant (no grant numbers) . PKD was supported by a NHMRC program grant and a senior research fellowship (1136680) . JAT was supported by a NHMRC program grant and an Investigator grant. PGE ac-knowledges the support of the Samuel Nissen Charitable Foundation.